BRIEF CURRICULUM VITAE

NAME: GARNET SUCK, PH.D.

PRESENT POSITION: Senior Transfusion Medicine Scientist
Patient Services Division and Group Director's Office
Blood Services Group (BSG)
Health Sciences Authority (HSA), Singapore

AND ADDRESS: 11 Outram Road
Singapore 169078
+65-62130824 (Phone)
+65-6223-8682 (Fax)
Garnet_suck@hsa.gov.sg
garnetsk@gmail.com

CURRENT POSITION AND PAST EMPLOYMENT HISTORY:

- Sept. 2006-present: Senior Transfusion Medicine Scientist, Blood Services Group, Health Sciences Authority, Singapore.
- 2006: Research Associate, Division of Biomedical Sciences, Johns Hopkins Ltd., Singapore.
- 2003–2006: Senior Research Fellow, Division of Hematology, Princess Margaret Hospital/ Ontario Cancer Institute, Toronto, Canada.
- 2002–2003: Postdoctoral Fellow, Health Science Centre, Univ. of Texas, Houston, USA.
- 2001–2002: Postdoctoral Fellow, Shands Cancer Center, Univ. of Florida, Gainesville, USA.

ACADEMIC QUALIFICATIONS:

- 1994: M.Sc. equivalent (Diploma in Biology), University of Hamburg, Germany.
- 2000: Ph.D. equivalent (Dr. rer. nat.), Medical University of Luebeck, Germany.

CURRENT JOB ACTIVITIES: Research: Translational cellular therapy research projects with emphasis on natural killer (NK) cells; Capabilities Development: Research Coordination and Strategic Foresight activities (Horizon Scanning).

SELECTED PUBLICATIONS**:**

- Suck, G., Oei, V. Y. S., Linn, Y. C., Ho, S. H., Chu, S.,Choong, A., and Koh, M. B. C. Interleukin-15 supports generation of highly potent clinical grade natural killer cells in long-term cultures for targeting hematological malignancies. *(Manuscript in press Exp. Hem.*).
- Niam, M., Linn, Y. C., Chong S. F., Lim T.-J., Chu, S., Choong, A., Niam, M., Suck, G., Chan, M., and Koh, M. B. C. Clinical scale expansion of cytokine-induced-killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy *(Manuscript in press Exp. Hem.*).
- Suck, G., Tan, S.-M., Chu, S., Niam, M., Vararattanavech, A., Lim, T. J., and Koh, M. B. C. 2011. Irradiated KHYG-1 and NK-92 represent different subtypes of LFA-1 mediated NK cell adhesiveness. *Frontiers in Bioscience (Elite Edition)*, E3: 166-78.
- Suck, G. and Koh, M. B. C. 2010. Emerging natural killer cell immunotherapies: large-scale ex vivo production of highly potent anticancer effectors. *Hematology/ Oncology and Stem Cell Therapy,* 3(3):pp. 135-42.

- Suck G. Natural killer cell activation. Book Essay. *Cancer Encyclopedia, Springer*. 2009. Schwab, Manfred (Ed.), 2nd ed., LXXXVII, p. 2028-2032.
- Suck, G., Novel approaches for using natural killer cells in cancer cell therapy. *Seminars in Cancer Biology.* 2006. 16 (5):412-418.
- Suck, G., Branch, D. R., and Keating, A., Irradiated KHYG-1 retains cytotoxicity: potential for adoptive immunotherapy with a natural killer cell line. *International Journal of Radiation Biology.* 2006. 82 (5): 355-361.
- Suck, G., Branch, D. R., Aravena, P., Mathieson, M., Helke, S., and Keating, A., Constitutively polarized granules prime KHYG-1 natural killer cells. *International Immunology* 2006. 18(9):1347-1354.
- Suck, G., Branch, D. R., Smyth, M. J., Miller, R.G., Vergidis, J., Fahim, J., and Keating, A, KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. *Experimental Hematology* 2005. 33 (10):1160-1171.
- Nicewonger, J., Suck, G., Bloch, D., and Swaminathan, S. Epstein-Barr virus (EBV) SM protein induces and recruits cellular Sp110b to stabilize mRNAs and enhance EBV lytic gene expression. *Journal of Virology* 2004. 78(17):9412-22.

EDITORIAL: Managing Editor, Frontiers in Bioscience (since May 2008) - Special Issue: 'Cellular Therapy& Vaccine Development'.

GRANT AWARDS (PRINCIPLE INVESTIGATOR)

- A*STAR/SIgN Collaborative Grant, 2011-2013. Evaluation of novel methods for large-scale isolation of human untouched regulatory T cells for cellular therapy (SIgN 10-032; S$567.731).
- HSA Research Fund, 2009-2010. Evaluation of a novel flow cytometric cytotoxicity assay for measurement of NK cytotoxicity against tumour target cells (S$50,000).
- Singapore Cancer Syndicate grant (TBS0095), 2007-2009. $CD56^+CD8^+$ and tumour-activated NK cells as potential candidates for cancer cellular therapy: molecular profiling and mechanistic analyses of their high cytotoxic potential (S$172,100).
- HSA Research Fund, 2008-2009. Evaluation of potent GMP-compliant culture conditions involving the novel cytokine IL-15 for generation of superior NK effectors (S$50,000).
- HSA Research Fund, 2006-2007. Enhancing NK cell cytotoxicity to improve current cancer cell therapies by ex vivo stimulation with neuropeptides (S$20,000).

FELLOWSHIP AWARDS

- Translational Research Fellowship, Haematology Oncology, Princess Margaret Hospital/Ontario Cancer Institute, Toronto, Canada, 2004-2005.
- Predoctoral Fellowship, State Schleswig Holstein, Germany, 1994-1995.

Conference abstracts published since 1997 with scientific societies, including Deutsche Gesellschaft für Genetik, American Association for Cancer Research, International Society for Cellular Therapy, American Society of Haematology, American Association of Immunologists, European Group for Blood and Marrow Transplantation, Singaporean Society for Immunology and Japanese Society for Immunology. Relevant invited speeches (Cellular therapy topics): Keynote Speech, Hong Kong Society for Immunology, 2010, Hong Kong; MACS Immunology Symposium, 2009, Taipei, Taiwan; BIT's World Cancer Congress, 2008, Shanghai, China, Speaker and Session Chair: Tumourimmunology. MACS Immunology Symposium; Miltenyi Biotec, Singapore, November 2007; Singapore-France International Immunology Symposium, May, 2007, A*STAR-SIgN, Singapore; University of Toronto, Toronto, Canada, 4th Annual International Symposium on Transfusion Immunology and Related Topics, 2006: Speech: 'Natural killer cells: promising candidates in cancer cell therapy'. Nabi Biopharmaceuticals, Rockville, MD, USA, 2004.